The investigators decided to use fractionated whole brain radiation doses of 1.8 Gy x 5 and 1.8 Gy x 3. Subjects will be followed with neurocognitive testing at 6 months post radiotherapy.
subjects 1-5 - 9Gy in 5 daily fractions
subjects 6-10 - 5.4Gy in 3 daily fractions
Age
50–95
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Clinical diagnosis of mild or moderate Alzheimer's disease.
Amyloid PET scan positivity.
Korean Mini-Mental State Examination score ≥10 and ≤24.
Clinical dementia rating scale 0.5, 1 or 2.
Ability to undergo neurocognitive assessment at baseline visit, alone or accomparined by a caregiver.
Ability to understand the clinical trial and give an informed consent
You may not be if
previous therapeutic whole brain irradiation
Evidence of seizure activity
Evidence of active dermatological skin disease of the scalp.
History of malignant tumors.
Pregnant or breastfeeding.
If the researcher determines that participation in this study is inadequate because of other findings that are considered clinically important.
